Drug Development

Trial Initiated Against Antibody-Mediated Stroke And Deep-Vein Thrombosis

Published in Vaccine Weekly, October 10th, 2001

La Jolla Pharmaceutical Company announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a Phase I/II clinical trial of LJP 1082, its clinical candidate for the treatment of antibody-mediated thrombosis, a life-threatening blood-clotting disorder.

"The successful filing of an IND for our second clinical candidate represents a major milestone. We now have two clinical candidates based on our proprietary Tolerance Technology approach," said Steven B. Engle, La Jolla Pharmaceutical Company. "Like our Phase III drug candidate for lupus, LJP 1082 is designed to reduce the production of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-10-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry